-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The safety and effectiveness of the AZD1222 (ChAdOx1nCoV-19) vaccine in the United States, Chile, and Peru who are at increased risk of being infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have not been confirmed
Infect
Recently, a research article was published in the top medical journal NEJM.
Prevent immunization
The study included a total of 32,451 participants and randomized the patients at a 2:1 ratio to vaccinate AZD1222 (21635 participants) or placebo (10816 participants)
In a series of population statistics subgroup, high vaccine efficacy is consistent
statistics
It can be seen that the AZD1222 vaccine can safely and effectively prevent symptomatic and severe Covid-19 in different groups of people, including the elderly
The AZD1222 vaccine can safely and effectively prevent symptomatic and severe Covid-19 in different groups of people, including the elderly
Original source: Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine Leave a message here